WHAT IS ALREADY KNOWN ON THIS TOPIC
Doxycycline (doxy) has demonstrated efficacy in reducing certain bacterial sexually transmitted infections (STIs), and some countries now recommend its use for post-exposure prophylaxis (PEP) in men who have sex with men (MSM) at increased STI risk.
In most Asia-Pacific countries, community-level data on doxy-PEP use are scarce.
WHAT THIS STUDY ADDS
This study revealed a moderate rate of doxy-PEP usage in MSM from the community in Hong Kong, despite the absence of recommended guidance.
Recent doxy-PEP use was more common among younger MSM, those self-identified as bisexual, MSM reporting chemsex or group sex and those with prior experience of HIV pre-exposure prophylaxis use.
HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY
These findings provide real-world evidence to inform future doxy-PEP guidance and implementation.
Background
Bacterial sexually transmitted infections (STIs) remain a significant public health issue, with the WHO estimating approximately 129 million chlamydia, 82 million gonorrhoea and 7.1 million…